Jonathan Block is a Managing Editor at Seeking Alpha. He specializes in finance and healthcare, with a focus on topics such as pharmaceutical regulation, mental health, and consumer health. His insights and analyses have been featured in The National Law Review, NewsBreak, Defiance Crescent News, JD Supra, and Seeking Alpha.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jonathan Block's coverage focuses on investment analysis, press releases, and data citations related to sales & marketing and automotive industries. He would likely be interested in pitches that provide in-depth analysis of stock performance, company news, and market trends within these sectors.
Given his focus on investment analysis and citation of data, Jonathan may find value in pitches from financial experts who can offer unique insights into the potential impact of various factors on stock performance or industry trends.
While Jonathan does not have a specific geographic focus mentioned but given the nature of his articles focusing mainly on companies listed in US stock exchanges (NASDAQ: HAS; NYSE: MTN), it is safe to assume he has an interest primarily in the US market.
This information evolves through artificial intelligence and human feedback. Improve this profile .
tanawit sabprasan AdaptHealth ( ADPT ) said some of its computer systems were hit in a cybersecurity attack in the middle of June, adding
By: Jonathan Block
Orthofix Medical ( OFIX ) is up ~10% in after-hours trading Thursday after announcing that CMS has withdrawn a final order that reclassified non-invasive bone growth stimulators.
By: Jonathan Block
design master Orthofix Medical ( OFIX ) is up 16% on Monday after CMS on July 1 decided to reverse a final order that reclassified non-invasive bone growth stimulators.
Bausch + Lomb ends BL1107 glaucoma eye drop after phase 2 miss, but continues as sustained-release implant for geographic atrophy with 2028 trials. Read more now.
By: Jonathan Block
Wirestock/iStock Editorial via Getty Images FedEx ( FDX ) has launched FedEx Life Sciences to handle the transportation of medical devices, pharmaceuticals, biologics, and clinical trial materials.
BioMarin’s Voxzogo sNDA for full FDA approval in achondroplasia is accepted, with a Feb. 28, 2027 action date. Read more here.
By: Jonathan Block
Federal appeals court revives Teva vs. Eli Lilly lawsuit over Forteo generic deal and FDA exclusivity delay. Read more here.
By: Jonathan Block
travellinglight/iStock via Getty Images The US FDA has approved Biogen ( BIIB ) and Eisai's ( ESALF ESAIY ) Leqembi Iqlik (lecanemab), a
ChrisChrisW GSK ( GSK ) said that interim results from the phase 2 AZER-1 trial showed that patients with a certain type of rectal cancer
HHS/VA MOU boosts psychedelic drug research and veteran mental health care. Read more here.
